Pamidronate therapy as prevention of bone loss following renal transplantation1
- 16 February 2000
- journal article
- Published by Elsevier in Kidney International
- Vol. 57 (2) , 684-690
- https://doi.org/10.1046/j.1523-1755.2000.t01-1-00890.x
Abstract
No abstract availableThis publication has 27 references indexed in Scilit:
- Post-transplantation bone disease: The role of immunosuppressive agents and the skeletonJournal of Bone and Mineral Research, 1996
- BONE FRACTURE AND OSTEODENSITOMETRY WITH DUAL ENERGY X-RAY ABSORPTIOMETRY IN KIDNEY TRANSPLANT RECIPIENTSTransplantation, 1994
- Loss of Regional Bone Mineral Density in the First 12 Months following Renal TransplantationNephron, 1994
- Glucocorticoid‐induced osteoporosis: pathogenesis, prevention and treatment, with special regard to the rheumatic diseasesJournal of Internal Medicine, 1993
- Fluoride-stimulated [3H] thymidine uptake in a human osteoblastic osteosarcoma cell line is dependent on transforming growth factor βJournal of Bone and Mineral Research, 1993
- Intravenous pamidronate in the treatment of osteoporosis associated with corticosteroid dependent lung disease: an open pilot study.Thorax, 1992
- Circulating osteocalcin in primary biliary cirrhosis following liver transplantation and during treatment with ciclosporinJournal of Hepatology, 1990
- One-shot high-dose pamidronate disodium (APD): effective, simple treatment for hypercalcaemia in haematological malignancyClinical and Laboratory Haematology, 1989
- Fluoride Directly Stimulates Proliferation and Alkaline Phosphatase Activity of Bone-Forming CellsScience, 1983
- Glucocorticoid Receptors and Actions in Subpopulations of Cultured Rat Bone CellsJournal of Clinical Investigation, 1979